| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
2,358 |
2,190 |
$296K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
2,147 |
1,920 |
$175K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
246 |
231 |
$11K |
| 96127 |
|
1,077 |
1,067 |
$5K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
64 |
62 |
$3K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
14 |
14 |
$2K |
| 81002 |
|
959 |
937 |
$2K |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
430 |
425 |
$2K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
14 |
14 |
$2K |
| 0012A |
|
34 |
34 |
$1K |
| G0008 |
Administration of influenza virus vaccine |
114 |
114 |
$1K |
| 0011A |
|
33 |
33 |
$1K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
78 |
39 |
$1K |
| 81000 |
|
221 |
219 |
$824.00 |
| 90686 |
|
49 |
49 |
$605.39 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
72 |
70 |
$510.00 |
| 0064A |
|
12 |
12 |
$506.83 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
121 |
118 |
$482.42 |
| Q3014 |
Telehealth originating site facility fee |
27 |
23 |
$225.00 |
| 93000 |
|
12 |
12 |
$196.62 |
| 3078F |
|
455 |
428 |
$0.00 |
| 99173 |
|
25 |
25 |
$0.00 |
| 99072 |
|
37 |
37 |
$0.00 |
| 3074F |
|
584 |
548 |
$0.00 |
| 91301 |
|
65 |
65 |
$0.00 |
| 1036F |
|
63 |
61 |
$0.00 |
| 91306 |
|
12 |
12 |
$0.00 |